{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:25:50Z","timestamp":1790623550915,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o de Amparo a Pesquisa do Estado de Minas Gerais","award":["PPM-00117-14"],"award-info":[{"award-number":["PPM-00117-14"]}]},{"name":"Funda\u00e7\u00e3o de Amparo a Pesquisa do Estado de Minas Gerais","award":["APQ-00968-14"],"award-info":[{"award-number":["APQ-00968-14"]}]},{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico - CNPq","award":["472438\/2013-1"],"award-info":[{"award-number":["472438\/2013-1"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.ejps.2016.05.022","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T17:55:07Z","timestamp":1464285307000},"page":"235-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pharmacokinetics\/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis"],"prefix":"10.1016","volume":"92","author":[{"given":"Julliana Ribeiro Alves","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela Costa","family":"C\u00e9sar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marliete Carvalho","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelly Queiroz","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Assun\u00e7\u00e3o","family":"Holanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais Hott","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Jos\u00e9 Cota","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiane Alves","family":"Paix\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerson Ant\u00f4nio","family":"Pianetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Assis","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2016.05.022_bb0005","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/bjh.12896","article-title":"Current status of antifungal resistance and its impact on clinical practice","volume":"166","author":"Alcazar-Fuoli","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","author":"Andes","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejps.2016.05.022_bb0015","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ja.2011.29","article-title":"PK-PD modeling of \u03b2-lactam antibiotics: In vitro or in vivo models?","volume":"64","author":"Araujo","year":"2011","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejps.2016.05.022_bb0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/cid\/cis529","article-title":"Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death","volume":"55","author":"Chen","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cit341","article-title":"Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii","volume":"57","author":"Chen","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0035","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1128\/CMR.00126-13","article-title":"Cryptococcus gattii Infections","volume":"27","author":"Chen","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2016.05.022_bb0040","series-title":"Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"10.1016\/j.ejps.2016.05.022_bb0045","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1128\/AAC.01115-12","article-title":"Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole","volume":"56","author":"Espinel-Ingroff","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents","volume":"27","author":"Felton","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2016.05.022_bb0055","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/jac\/dkt114","article-title":"The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii","volume":"68","author":"Ferreira","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0060","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1128\/AAC.00466-15","article-title":"Heteroresistance to itraconazole alters the morphology and increases the virulence of Cryptococcus gattii","volume":"59","author":"Ferreira","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S1473-3099(14)70945-4","article-title":"Management of Cryptococcus gattii meningoencephalitis","volume":"15","author":"Franco-Paredes","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0070","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s10096-013-1915-8","article-title":"Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment","volume":"32","author":"Gullo","year":"2013","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ijantimicag.2008.11.007","article-title":"Cryptococcus neoformans serotype A and Cryptococcus gattii serotype B isolates differ in their susceptibilities to fluconazole and voriconazole","volume":"33","author":"Khan","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejps.2016.05.022_bb0080","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Laborin","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0085","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1128\/AAC.01354-13","article-title":"Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0090","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s10096-011-1488-3","article-title":"Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities","volume":"31","author":"Matos","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2672.2011.05186.x","article-title":"Quantitative evaluation of cryptococcal pathogenesis and antifungal drugs using a silkworm infection model with Cryptococcus neoformans","volume":"112","author":"Matsumoto","year":"2011","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0100","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s10096-010-1034-8","article-title":"Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii","volume":"29","author":"Mendes","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ejps.2016.05.022_bb0105","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of fluconazole area under the concentration-time curve\/MIC and Dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1128\/JCM.01747-08","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing","volume":"47","author":"Pfaller","year":"2009","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0115","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1128\/AAC.06098-11","article-title":"Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii","volume":"56","author":"Santos","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejps.2016.05.022_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112669","article-title":"Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine cryptococcosis","volume":"9","author":"Santos","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2016.05.022_bb0125","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/jac\/dkh361","article-title":"Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002","volume":"54","author":"Sar","year":"2004","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2147\/CLEP.S38850","article-title":"Cryptococcal meningitis: epidemiology and therapeutic options","volume":"6","author":"Sloan","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0135","article-title":"Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest","volume":"9","author":"Smith","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2016.05.022_bb0140","first-page":"242","article-title":"Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing","volume":"31","author":"Soares","year":"2008","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.ejps.2016.05.022_bb0145","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1128\/AAC.00216-13","article-title":"Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints","volume":"57","author":"Sudan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0150","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population pharmacokinetics of fluconazole in young infants","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2016.05.022_bb0155","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1128\/AAC.00102-15","article-title":"Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation","volume":"59","author":"Watt","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098716302032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T21:22:16Z","timestamp":1572729736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098716302032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"alternative-id":["S0928098716302032"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.022","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics\/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2016.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}